The FDA decision on Albireo Pharma Inc.’s (ALBO) drug candidate Bylvay, known generically as Odevixibat, is expected to be announced on July 20.The company is seeking approval of Bylvay for the treatment of progressive familial intrahepatic cholestasis (PFIC), wherein patients have liver cells that are less able to secrete bile and have impaired bile flow, resulting in the buildup of bile in liver cells.Bylvay, known generically as Odevixibat, is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT) that acts locally in the distal ileum, reducing the reuptake of bile acids and increasing the clearance of bile acids through the colon.According to a report published by Coherent Market Insights, the progressive familial intrahepatic cholestasis treatment market valued at $29.6 million in 2020, is expected to be valued at $290.8 million in 2027.ALBO closed Wednesday’s (Jun.23, 2021) trading at $35.53, up 2.27%.